J. Michael Carmena is Principal Executive Officer, Director of the Company. Prior to joining the Company, Mr. Carmena served as Senior Director, Business & Sales Operations, of Smith and Nephew plc, formerly known as Healthpoint Biotherapeutics. Mr. Carmena previously served Healthpoint Biotherapeutics as Senior Director, Finance & Administration (from 2008 to 2010) and as Controller (from 1998 to 2008). Mr. Carmena began his career at Arthur Andersen & Co., after graduating, magna cum laude, with a BBA in Accounting from Texas Christian University in 1978.
J Carmena is 63, he's been the Principal Executive Officer und Director of Sanara MedTech since 2019. There are 1 older and 6 younger executives at Sanara MedTech. The oldest executive at Sanara MedTech Inc. is Ronald T. Nixon, 65, who is the Exec. Chairman.
J's mailing address filed with the SEC is 1200 SUMMIT AVE, SUITE 414, FORT WORTH, TX, 76102.
Over the last 5 years, insiders at Sanara MedTech have traded over $168,795 worth of Sanara MedTech stock. The most active insiders traders include Eric D Tanzberger, Ronald T Nixon und James W Stuckert. On average, Sanara MedTech executives and independent directors trade stock every 55 days with the average trade being worth of $25,133. The most recent stock trade was executed by Michael D. Mc Neil on 12 April 2023, trading 1,000 units of SMTI stock currently worth $6,000.
Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako¯s Antimicrobial Skin and Wound Irrigation Solution. The company also provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a single layer sheet of amnion tissue. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
Sanara MedTech executives and other stock owners filed with the SEC include: